No image available for this title

LITERATURE

Meropenem–vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria


Meropenem–vaborbactam is a fixed-dose combination product of a carbapenem and a cyclic boronic
acid β-lactamase inhibitor with potent in vitro activity against Klebsiella pneumoniae carbapenemaseproducing carbapenem-resistant Enterobacteriaceae (CRE). The efficacy of meropenem–vaborbactam for
the treatment of complicated urinary tract infections and acute pyelonephritis was demonstrated in a
Phase III trial (TANGO I). Preliminary data from TANGO II, a separate Phase III study, support the efficacy of meropenem–vaborbactam for the treatment of infections caused by CRE. Overall, meropenem–
vaborbactam appears to be safe and well tolerated. It has favorable toxicity, pharmacokinetic and pharmacodynamic profiles compared with other antibiotics with activity against CRE. Meropenem–vaborbactam
is an important addition to the current armamentarium of antimicrobial agents with activity against K.
pneumoniae carbapenemase-producing CRE


Availability

Tripenem-008Available

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
Future Microbiol. (2018) 13(9), 971–983
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous